Argus Research Maintains Buy on CVS Health, Raises Price Target to $114
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice TargetHot
Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.
Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.